Navigation Links
Need for Cost-effective Hearing Implants

Nearly a million children in India suffering from serious hearing problems could have been benefited by cochlear implants, // but the prohibitive cost of such surgery is keeping them away, health experts said Saturday.

"Nearly 10 million people in India suffer some kind of hearing problems and about a million are children and they need to undergo cochlear implant surgery. But the high cost of the device is proving a hindrance," said Vice Admiral V.K. Singh, director general of Armed Forces Medical Services.

The surgery entails implanting a small electronic device inside the ear while a magnetic microprocessor is placed outside the ear to amplify external sounds, digitize them and send radio signals to the deaf person's ear to enable them to listen.

"The general public in India cannot afford such an implant costing about Rs.600,000. What we need is low cost implants, awareness and parental support for those affected by such problems," Singh said at a function of Cochlear, the Australian manufacturer.

R.C. Deka, head of the department of ENT (ear, nose and throat) and dean of All India Institute of Medical Sciences (AIIMS), said: "We have conducted 150 such implants, including 110 children, at subsidized cost."

"The device from the Australian company Cochlear is the most advanced and reliable product and occupies nearly 85 percent of the Indian market. Though its cost is a little high, yet it is cheaper than in other countries," said A.K. Lahiri, senior professor at Sir Ganga Ram Hospital, at the function to mark the 1,000th cochlear implant surgery using the Australian device.

Ash Adarkar, area manager south Asia of the Australian company, told IANS: "The machine is labor and time -intensive. It takes nearly six weeks to manufacture one device. Though the international cost is over Rs.750,000, we are selling the device in India for Rs.512,000." S.S. Panwar, head of ENT and Neu
'"/>




Page: 1 2

Related medicine news :

1. Cost-effective antibiotics for sinusitis treatment
2. Cost-effective Meningitis Vaccine To Be Launched In Africa
3. Lowering Contrast Material Injection in Aged Patients is Cost-effective and can Offset Risks
4. Prevention (Of AIDS) By Circumcision More Cost-effective Than Cure
5. One-time Melanoma Screening Appears to Be Cost-effective for Elderly People
6. Hearing loss can be detected by simple screening
7. A High-Definition Hearing Aid that thinks for you
8. Vitamin E Could Restore Sudden Hearing Loss
9. Hearing loss can happen from regular exposure to carbon monoxide
10. Studies On Hearing Loss Discovers New Causes
11. Possibility Of Treatment For Permanent Hearing Loss
Post Your Comments:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 1Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 3Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 4Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 1Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 2
Other Medicine Technology:NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 2NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 3NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 4NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 5NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 6Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 2Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 3Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 4Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 5Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 6